Humanwell Healthcare (Group) Co., Ltd. (600079.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 18.42

From 52W high−22.49%

Volume4.16M

Market capCNY 29.14B

P/E (TTM)15.7x

P/S (TTM)1.3x

Div yield2.60%

Key dataSep 18, 2026

Open

CNY 18.42

From 52W high

−22.49%

Volume

4.16M

Market cap

CNY 29.14B

ValuationView details →

P/E (Fwd)

33.0x

EV/EBITDA

8.9x

P/E (TTM)

15.7x

RSI (14)

52.8

MomentumView details →

1D Return

−0.22%

YTD Return

+1.93%

ValuationView details →

P/E (Fwd)

33.0x

P/E (TTM)

15.7x

EV/EBITDA

8.9x

EV/Sales

1.6x

P/S (TTM)

1.3x

P/B (TTM)

1.6x

ProfitabilityView details →

Gross Margin

48.46%

Net Margin

7.95%

EBITDA Margin

17.62%

ROE (TTM)

9.80%

ROA (TTM)

5.06%

Asset Turnover

0.64x

GrowthView details →

Revenue YoY

−5.08%

EPS YoY

+37.64%

FCF YoY

+141.85%

Revenue CAGR 3Y

+2.37%

EPS CAGR 3Y

−9.54%

EBITDA YoY

—

MomentumView details →

1D Return

−0.22%

YTD Return

+1.93%

1Y Return

−14.58%

RSI (14)

52.8

vs 50D SMA

+2.14%

vs 200D SMA

+0.94%

Capital & dividendView details →

Debt/Equity

0.45x

Current Ratio

1.92x

Quick Ratio

1.62x

Div Yield

2.60%

Div Rate

CNY 0.48

Div Growth 1Y

−47.54%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.41

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

23.93B

Net Income (TTM)

1.90B

Op. CF (TTM)

3.14B

Latest newsMore news →

ST Renfu's controlled subsidiary Yichang Renfu announced that its drug RFUS-949 tablets have entered Phase II clinical trials for the treatment of acute and chronic pain.18d ago

Humanwell Healthcare's subsidiary Yichang Humanwell Pharmaceutical received acceptance of its marketing authorization application for pregabalin extended-release tablets from China's National Medical Products Administration.21d ago

Similar companies

Zoetis Inc.ZTS 达仁堂600329.SH China Resources Pharmaceutical Group Limited03320.HK China Medical System Holdings Limited00867.HK 白云山600332.SH 华海药业600521.SH Find similar companies →

Latest newsMore news →

ST Renfu's controlled subsidiary Yichang Renfu announced that its drug RFUS-949 tablets have entered Phase II clinical trials for the treatment of acute and chronic pain.18d ago Humanwell Healthcare's subsidiary Yichang Humanwell Pharmaceutical received acceptance of its marketing authorization application for pregabalin extended-release tablets from China's National Medical Products Administration.21d ago ST Renfu's wholly-owned subsidiary Wuhan Puke obtained a drug registration certificate for Vinorelbine Tartrate Soft Capsules, valid until July 20, 2031.59d ago